November 3, 2025 — Leads & Copy — Savara Inc. (Nasdaq: SVRA) will participate in fireside chats at two upcoming healthcare conferences. Members of the management team will host 1×1 meetings.
Fireside Chats:
Guggenheim 2nd Annual Healthcare Innovation Conference
November 10, 2025, 8:30 a.m. ET
Jefferies London Healthcare Conference
November 19, 2025, 12:00 p.m. GMT
The live webcasts and replays will be available on the “Events & Presentations” section of Savara’s website and will be archived for 90 days.
Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Their lead program, MOLBREEVI*, is in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). MOLBREEVI is delivered via a proprietary investigational eFlow® Nebulizer System. Savara’s management team has significant experience in rare respiratory diseases and pulmonary medicine.
*MOLBREEVI is the FDA and EMA conditionally accepted trade name for molgramostim inhalation solution. It is not approved in any indication. MOLBREEVI is a trademark of Savara Inc.
Source: Savara Inc.
